☰

Empresas y finanzas

Covidien Introduces Versaport TM Plus Bladeless Trocars to Surgical Markets Globally


    Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced that its Surgical Devices business unit has launched the Versaport TM Plus Bladeless Trocar line for the minimally invasive surgical market worldwide.

    The Versaport TM Plus Bladeless Trocars offer surgeons greater precision and control, low insertion force, a small facial defect and superior port fixation with Covidien´s proprietary secure entry technology. When the Versaport TM Plus Bladeless Trocar is combined with Step TM technology in VersaStep TM Plus, Covidien sets the standard for safety in laparoscopic entry and provides medical professionals with a comprehensive line of bladeless access devices.

    "Our innovative Versaport TM Plus Bladeless Trocars are the latest example of Covidien´s collaboration with customers to offer access solutions that give them the sense of confidence, security and control that they have been asking for," said Scott Flora, President, Surgical Devices, Covidien. "This product launch, when coupled with some of our current technologies, significantly enhances our position in the rapidly growing market for bladeless access devices and trocars."

    Versaport TM Plus Bladeless Trocars can be used in conventional and advanced laparoscopic procedures in general, bariatric, colon and rectal, gynecological and urological surgery.

    ABOUT COVIDIEN

    Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry–leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2007 revenue of nearly $9 billion, Covidien has more than 42,000 employees worldwide in 57 countries, and its products are sold in over 130 countries. Please visit www.covidien.com to learn more about our business.